SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BriBear who wrote (3480)12/31/1997 12:45:00 PM
From: Oliver & Co  Read Replies (1) of 6136
 
"Johns Hopkins AIDS Program for Medicaid Patients Efficacious and
Cost-Effective"
Reuters Health Information Services (12/30/97)
ÿÿÿÿ An article in the December 25th issue of Disease Management
News indicates that a new AIDS program for Medicaid patients has
both saved money and increased patient survival. The article
noted that while Medicaid pays nearly $23,000 per patient for
AIDS patients nationwide each year, the average cost of treatment
with the Moore Options AIDS program at Johns Hopkins Hospital in
Maryland is only about $10,000 per patient per year. According to
Dr. John Bartlett, head of the infectious disease division at the
university, the AIDS program helped increase the survival rate of
AIDS patients from inner-city Baltimore, so that patients in that
system had the same likelihood of survival, regardless of
earnings, gender, race, or risk level.
======================================================================

I wonder what combos they are giving patients, to be able to have such low cost.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News